Ovid Therapeutics (NASDAQ:OVID) Inc. is a clinical‐stage biopharmaceutical company dedicated to developing therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, Ovid applies a precision medicine approach to address serious conditions with high unmet need, focusing primarily on pediatric and adult patients affected by developmental and epileptic encephalopathies and other central nervous system (CNS) diseases.
The company’s lead product, Ztalmy (fenfluramine) oral solution, received U.S. Food and Drug Administration approval for the treatment of seizures associated with Dravet syndrome and Lennox‐Gastaut syndrome. Ztalmy represents the first FDA‐approved therapy in its class for these indications and is supported by Phase 3 clinical data demonstrating significant reductions in seizure frequency. In addition to commercialization activities, Ovid is advancing OV935, a negative allosteric modulator of AMPA receptors in clinical development for fragile X syndrome and autism spectrum disorder, along with earlier‐stage programs targeting other rare neurologic and neurodevelopmental disorders.
Ovid Therapeutics serves patients and healthcare providers across the United States and has established strategic partnerships to support commercialization and further development in Europe and other international markets. The company collaborates with global biopharma partners to leverage regulatory expertise and distribution networks, ensuring broader access to its approved and investigational medicines. This collaborative model underpins Ovid’s goal of expanding treatment options for underserved patient populations worldwide.
Leadership at Ovid combines deep experience in neuroscience drug development with a commitment to rare disease research. Jeremy M. Levin, the company’s Chairman and Chief Executive Officer, brings more than 30 years of biopharma leadership, having held executive roles at Teva, Biogen and other global healthcare firms. Supporting the management team are seasoned professionals in clinical development, regulatory affairs and commercial operations, all aligned behind Ovid’s mission to bring innovative therapies to patients with serious neurological conditions.
